Form 4: Veracyte Director Evan Jones Executes Stock Sales Under 10b5-1 Plan

Director Evan Jones reported multiple sales of Veracyte (VCYT) common stock and exercised stock options, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Evan Jones, a director of Veracyte, Inc. (VCYT), reported the sale of common stock on August 12 and 13, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2024.
• On August 12, 2024, 99 shares were sold at a weighted average price of $30.0051, and 101 shares were sold at a weighted average price of $30.005.
• On August 13, 2024, a series of sales occurred at varying weighted average prices: 2,931 shares at $31.1859, 16,838 shares at $32.3584, 688 shares at $32.7678, and 3,869 shares at $31.185.
• Additionally, on August 13, 2024, Jones exercised a stock option to acquire 8,486 shares at $10.41 per share.
• Following these transactions, Jones directly owns 51,869 shares and indirectly owns 5,173 shares through jVen Capital, LLC.
• The reporting person is the sole managing member of jVen Capital, LLC.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading program. The sales themselves could be seen as slightly negative, but the 10b5-1 plan mitigates this.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Negatives

• The sales by a director could be perceived negatively by some investors, although the 10b5-1 plan mitigates this concern.

Risks

• Continued stock sales by insiders, even under a 10b5-1 plan, could exert downward pressure on the stock price.

Industry Context

Insider trading activity is always closely watched in the biotech industry, especially for companies like Veracyte that are in a growth phase. Sales by insiders can sometimes be interpreted negatively, but pre-planned trading programs like 10b5-1 plans are designed to avoid such perceptions.

Comparison to Industry Standards

• Comparing insider trading activity at Veracyte to companies like Exact Sciences (EXAS) or Genomic Health (GHDX) (now part of Exact Sciences) would provide a benchmark.
• Reviewing the frequency and size of insider sales at these comparable companies can help determine if the activity at Veracyte is typical or unusual.
• Analyzing the use of 10b5-1 plans among executives at these companies can also provide context.

Stakeholder Impact

• The stock sales could have a minor impact on shareholder sentiment, although the 10b5-1 plan should reassure investors that the transactions are not based on inside information.

Key Dates